Surgery and OncologySurgery and OncologyХирургия и онкология2949-5857Publishing House ABV Press910.17650/2220-3478-2014-0-1-16-22ORIGINAL REPORTSОРИГИНАЛЬНЫЕ ИССЛЕДОВАНИЯIMMEDIATE RESULTS OF HEPATECTOMY FOR METASTATIC COLORECTAL CANCERНЕПОСРЕДСТВЕННЫЕ РЕЗУЛЬТАТЫ РЕЗЕКЦИЙ ПЕЧЕНИ ПО ПОВОДУ МЕТАСТАЗОВ КОЛОРЕКТАЛЬНОГО РАКАPatyutkoYu. I.ПатюткоЮ. И.
Russian Federation
dr.alexp@gmail.comKotelnikovA. G.КотельниковА. Г.
Russian Federation
dr.alexp@gmail.comMamontovK. G.МамонтовК. Г.
Russian Federation
dr.alexp@gmail.comPonomarenkoA. A.ПономаренкоА. А.
Russian Federation
dr.alexp@gmail.comLazarevA. F.ЛазаревА. Ф.
Russian Federation
dr.alexp@gmail.comN. N. Blokhin Russian Cancer Research Center, Russian Academy of Medical Sciences, MoscowФГБУ «РОНЦ им. Н. Н. Блохина» РАМН, МоскваAltai Branch, N. N. Blokhin Russian Cancer Research Center, Russian Academy of Medical Sciences, BarnaulАлтайский филиал «РОНЦ им. Н. Н. Блохина» РАМН, БарнаулState Coloproctology Research Center, Ministry of Health of Russia, MoscowФГБУ «Государственный научный центр колопроктологии» Минздрава России, Москва230220143116222302201523022015Copyright ©; 2014, ABV-pressCopyright ©; 2014, АБВ-пресс2014ABV-pressАБВ-прессhttps://onco-surgery.info/jour/about/editorialPolicieshttps://onco-surgery.info/jour/article/view/9

Incorporation of bevacizumab to preoperative regional chemotherapy (CT) failed to increase the volume of intraoperative blood loss and the frequency of postoperative complications. Addition of the drug in the regional CT group significantly enhanced the rate of its effect up to 64 % and that of grade III medical pathomorphism up to 55 %. Regardless of the pattern of surgeries, the rate of complications after extended hepatectomy did not differ significantly in the treatment groups. Irrespective of treatment, the rate of acute liver failure rose when the volume of surgery was increased from conventional hemihepatectomy to extended hemihepatectomy. Acute liver failure was prominent (21%) among the complications in the treatment group. The highest incidence of acute liver failure in the comparable groups was observed in the preoperative regional CT group.

Включение бевацизумаба в состав дооперационной регионарной химиотерапии (ХТ) не приводит к повышению объема интраоперационной кровопотери и не увеличивает частоту послеоперационных осложнений. Добавление к ХТ в группе регионарной ХТ бевацизумаба достоверно увеличивает частоту эффекта до 64 % и частоту лекарственного патоморфоза III степени – до 55 %. Уровень осложнений после обширных резекций печени, независимо от характера операций, в группах лечения достоверно не различается. При увеличении объема операции от стандартной гемигепатэктомии (ГГЭ) к расширенной ГГЭ, независимо от лечения, достоверно увеличивается частота острой печеночной недостаточности. Ведущее место среди осложнений в группах лечения занимает острая печеночная недостаточность – 21 %. Наибольшая частота острой печеночной недостаточности в сравниваемых группах наблюдается в группе с дооперационной регионарной ХТ.

colorectal cancer liver metastasespreoperative chemotherapycomplicationsметастазы колоректального рака в печенидооперационная химиотерапияосложнения1. Boyle P., Ferlay J. Cancer incidence and mortality in Europe, 2004. Ann Oncol 2005 Mar;16(3):481–8. doi:10.1093 / annonc / mdi098. Accessed 5.16.07.Boyle P., Ferlay J. Cancer incidence and mortality in Europe, 2004. Ann Oncol 2005 Mar;16(3):481–8. doi:10.1093 / annonc / mdi098. Accessed 5.16.07.2. Kokudo N., Tada K., Seki M. et al. Anatomical major resection versus nonanatomical limited resection for liver metastases from colorectal carcinoma. Am J Surg 2001;181(2):153–9.Kokudo N., Tada K., Seki M. et al. Anatomical major resection versus nonanatomical limited resection for liver metastases from colorectal carcinoma. Am J Surg 2001;181(2):153–9.3. Kubota K. I., Makuuchi M., Kusaka K. et all. Measurement of liver volume and hepatic functional reserve as a guide to decision-making in resection surgery for hepatic tumors. Hepatology 1997;26:1176–81.Kubota K. I., Makuuchi M., Kusaka K. et all. Measurement of liver volume and hepatic functional reserve as a guide to decision-making in resection surgery for hepatic tumors. Hepatology 1997;26:1176–81.4. Rudroff C., Altendorf-Hoffmann A., Stangl R., Scheele J. Prospective randomized trial on adjuvant hepatic-artery infusion chemotherapy after R0 resection of colorectal liver metastases. Langenbecks Arch Surg 1999;384(3):243–9.Rudroff C., Altendorf-Hoffmann A., Stangl R., Scheele J. Prospective randomized trial on adjuvant hepatic-artery infusion chemotherapy after R0 resection of colorectal liver metastases. Langenbecks Arch Surg 1999;384(3):243–9.5. Давыдов М. И., Аксель Е. М. Статистика злокачественных новообразований в России и странах СНГ в 2005 г. Вестник ГУ РОНЦ им. Н. Н. Блохина РАМН 2007;18(2). Прил. 1Давыдов М. И., Аксель Е. М. Статистика злокачественных новообразований в России и странах СНГ в 2005 г. Вестник ГУ РОНЦ им. Н. Н. Блохина РАМН 2007;18(2). Прил. 16. Lawes D., Taylor I. Chemotherapy for colorectal cancer – an overview of current management for surgeons. Eur J Surg Oncol 2005;31(9):932–41.Lawes D., Taylor I. Chemotherapy for colorectal cancer – an overview of current management for surgeons. Eur J Surg Oncol 2005;31(9):932–41.7. Azoulay D., Andreani P., Maggi U. et all. Combined liver resection and reconstruction of the supra-renal vena cava: the Paul Brousse experience. Ann Surg 2006;244(1):80–8.Azoulay D., Andreani P., Maggi U. et all. Combined liver resection and reconstruction of the supra-renal vena cava: the Paul Brousse experience. Ann Surg 2006;244(1):80–8.8. Минимальные клинические рекомендации Европейского Общества Медицинской Онкологии (ЕСМО). Редакторы русского перевода С. А. Тюляндин, Н. И. Переводчикова, Д. А. Носов. М.: Изд. группа РОНЦ им. Н. Н. Блохина РАМН, 2008. 146 с.Минимальные клинические рекомендации Европейского Общества Медицинской Онкологии (ЕСМО). Редакторы русского перевода С. А. Тюляндин, Н. И. Переводчикова, Д. А. Носов. М.: Изд. группа РОНЦ им. Н. Н. Блохина РАМН, 2008. 146 с.9. Brown К., Kemeny N., Berger M. F. et al. Obstructive jaundice in patients receiving hepatic artery infusional chemotherapy: Etiology, treatment implications, and complications after transhepatic biliary draiage. J Vasc Intervent Radiol l997;8(2):229–34.Brown К., Kemeny N., Berger M. F. et al. Obstructive jaundice in patients receiving hepatic artery infusional chemotherapy: Etiology, treatment implications, and complications after transhepatic biliary draiage. J Vasc Intervent Radiol l997;8(2):229–34.10. Lygidakis N. J., Singh G., Bardaxoglou E. et al. Two-stage liver surgery for advanced liver metastasis synchronous with colorectal tumor. Hepatogastroenterology 2004;51(56):413–8.Lygidakis N. J., Singh G., Bardaxoglou E. et al. Two-stage liver surgery for advanced liver metastasis synchronous with colorectal tumor. Hepatogastroenterology 2004;51(56):413–8.11. Falcone A., Ricci S., BrunettiI. et al. Phase III trial of infusional fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) compared with infusional fluorouracil, leucovorin, and irinotecan (FOLFIRI) as first-line treatment for metastatic colorectal cancer: the Gruppo Oncologico Nord Ovest. J Clin Oncol 2007;25(13):1670–6.Falcone A., Ricci S., BrunettiI. et al. Phase III trial of infusional fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) compared with infusional fluorouracil, leucovorin, and irinotecan (FOLFIRI) as first-line treatment for metastatic colorectal cancer: the Gruppo Oncologico Nord Ovest. J Clin Oncol 2007;25(13):1670–6.12. Lievre A., Bachet J. B., Boige V. et al. KRAS mutation as an independent prognostic factor in patients with advanced colorectal cancer treatment with cetuximab. J Clin Oncol 2008;26(3):374–9.Lievre A., Bachet J. B., Boige V. et al. KRAS mutation as an independent prognostic factor in patients with advanced colorectal cancer treatment with cetuximab. J Clin Oncol 2008;26(3):374–9.13. Nakamura S., Yokoi Y., Suzuki S. et al. Results of extensive surgery for liver metastases in colorectal carcinoma. Brit J Surg 1992;79 (1):35–8.Nakamura S., Yokoi Y., Suzuki S. et al. Results of extensive surgery for liver metastases in colorectal carcinoma. Brit J Surg 1992;79 (1):35–8.14. Zacharias T., Jaeck D., Oussoultzoglou E. et al. First and repeat resection of colorectal liver metastases in elderly patients. Ann Surg 2004;240(5):858–65.Zacharias T., Jaeck D., Oussoultzoglou E. et al. First and repeat resection of colorectal liver metastases in elderly patients. Ann Surg 2004;240(5):858–65.15. Fernandez F. G., Ritter J., Goodwin J. W. et al. Effect of steatohepatitis associated with irinotecan or oxaliplatin pretreatment on resectability of hepatic colorectal metastases. J Am Coll Surg 2005;200 (6):845–53.Fernandez F. G., Ritter J., Goodwin J. W. et al. Effect of steatohepatitis associated with irinotecan or oxaliplatin pretreatment on resectability of hepatic colorectal metastases. J Am Coll Surg 2005;200 (6):845–53.16. Figueras J., Valls C., Rafecas A. et al. Resection rate and effect of postoperative chemotherapy on survival after surgery for colorectal liver metastases. Br J Surg 2001;88(7):980–5.Figueras J., Valls C., Rafecas A. et al. Resection rate and effect of postoperative chemotherapy on survival after surgery for colorectal liver metastases. Br J Surg 2001;88(7):980–5.17. Патютко Ю. И. Хирургическое л ечение злокачественных опухолей печени. М.: Практическая медицина, 2005.Патютко Ю. И. Хирургическое л ечение злокачественных опухолей печени. М.: Практическая медицина, 2005.18. Bijelic L., Yan T. D., Sugarbaker P. H. Failure analysis of recurrent disease following complete cytoreduction and perioperative intraperitoneal chemotherapy in patients with peritoneal carcinomatosis from colorectal cancer. Ann Surg Oncol 2007 Aug;14(8):2281–8.Bijelic L., Yan T. D., Sugarbaker P. H. Failure analysis of recurrent disease following complete cytoreduction and perioperative intraperitoneal chemotherapy in patients with peritoneal carcinomatosis from colorectal cancer. Ann Surg Oncol 2007 Aug;14(8):2281–8.19. Kato T., Yasui K., Hirai T. et al. Therapeutic results for hepatic metastases of colorectal cancer with special reference to effectiveness of hepatectomy: analysis of prognostic factors for 763 cases recorded at 18 institution. Dis Colon Rectum 2003;46(10 Suppl):S22–31.Kato T., Yasui K., Hirai T. et al. Therapeutic results for hepatic metastases of colorectal cancer with special reference to effectiveness of hepatectomy: analysis of prognostic factors for 763 cases recorded at 18 institution. Dis Colon Rectum 2003;46(10 Suppl):S22–31.20. Tomlinson J. S., Jarnagin W. R., DeMatteo R. P. et al. Actual 10-year survival after resection of colorectal liver metastases defines cure. J Clin Oncol 2007;25(29):4575–80.Tomlinson J. S., Jarnagin W. R., DeMatteo R. P. et al. Actual 10-year survival after resection of colorectal liver metastases defines cure. J Clin Oncol 2007;25(29):4575–80.21. Yan B., Clingan P., Morris D. Hepatic cryotherapy and regional chemo-therapy with or without resection for liver metastases from colorectal carci-noma. how many are too many? Cancer 2003 Jul 15;98(2):320–30.Yan B., Clingan P., Morris D. Hepatic cryotherapy and regional chemo-therapy with or without resection for liver metastases from colorectal carci-noma. how many are too many? Cancer 2003 Jul 15;98(2):320–30.22. Abdalla E. K., Adam R., Bilchik A. J. et al. Improving resectability of hepatic colorectal metastases: expert consensus statement. Ann Surg Oncol 2006;13(10):1271–80.Abdalla E. K., Adam R., Bilchik A. J. et al. Improving resectability of hepatic colorectal metastases: expert consensus statement. Ann Surg Oncol 2006;13(10):1271–80.23. Lencioni R., Cioni D., Bartolozzi C. (Eds.). Focal liver lesions: detection, characterization, ablation. Berlin Heidelberg: Springer Verlag, 2005.Lencioni R., Cioni D., Bartolozzi C. (Eds.). Focal liver lesions: detection, characterization, ablation. Berlin Heidelberg: Springer Verlag, 2005.24. Malafosse R., Penna C., Sa Cunha A., Nordlinger B. Surgical management of hepatic metastases from colorectal malignancies. AnnOncol 2001;12 (7):887–94.Malafosse R., Penna C., Sa Cunha A., Nordlinger B. Surgical management of hepatic metastases from colorectal malignancies. AnnOncol 2001;12 (7):887–94.25. Adam R., Hagopian E. J., Linhares M. et al. A comparison of percutaneous cryosurgery and percutaneous radiofrequency for unresectable hepatic malignancies. Arch Surg 2002;137(12):1332–9.Adam R., Hagopian E. J., Linhares M. et al. A comparison of percutaneous cryosurgery and percutaneous radiofrequency for unresectable hepatic malignancies. Arch Surg 2002;137(12):1332–9.26. Colucci G., Gebbia V., Paoletti G. et al. Phase III randomized trial of FOLFIRI versus FOLFOX4 in the treatment of advanced colorectal cancer: a multicenter study of the Gruppo Oncologico Dell’Italia Meridionale. J Clin Oncol 2005;23(22):4866–75.Colucci G., Gebbia V., Paoletti G. et al. Phase III randomized trial of FOLFIRI versus FOLFOX4 in the treatment of advanced colorectal cancer: a multicenter study of the Gruppo Oncologico Dell’Italia Meridionale. J Clin Oncol 2005;23(22):4866–75.27. Van Cutsem E., Tabernero J., Lakomy R. et al. Intravenous (IV) aflibercept versus placebo in combination with irinotecan / 5-FU (FOLFIRI) for second line treatment of metastatic colorectal cancer (MCRC): results of a multinational phase III trial (EFC 10262-VELOUR). Ann Oncol 2011;22 (suppl): v18.Van Cutsem E., Tabernero J., Lakomy R. et al. Intravenous (IV) aflibercept versus placebo in combination with irinotecan / 5-FU (FOLFIRI) for second line treatment of metastatic colorectal cancer (MCRC): results of a multinational phase III trial (EFC 10262-VELOUR). Ann Oncol 2011;22 (suppl): v18.28. Zarate R., Rodriguez J., Bandres E. et al. Oxaliplatin, irinotecan and capecitabine as first-line therapy metastatic colorectal cancer (mCRC): a dose-finding study and pharmacogenomic analysis. Br J Cancer 2010;102(6):987–94.Zarate R., Rodriguez J., Bandres E. et al. Oxaliplatin, irinotecan and capecitabine as first-line therapy metastatic colorectal cancer (mCRC): a dose-finding study and pharmacogenomic analysis. Br J Cancer 2010;102(6):987–94.29. Kemeny N. E. Current approaches for liver-only metastases in colorectal cancer. Com Oncology 2006 June;3(6):26–35.Kemeny N. E. Current approaches for liver-only metastases in colorectal cancer. Com Oncology 2006 June;3(6):26–35.30. Wei A. C., Greig P. D., Grant D. et al. Survival after hepatic resection for colorectal metastases: a 10-year experience. Ann Surg Oncol 2006;13(5):668–76.Wei A. C., Greig P. D., Grant D. et al. Survival after hepatic resection for colorectal metastases: a 10-year experience. Ann Surg Oncol 2006;13(5):668–76.31. Hecht J. R., Mitchell E., Chidiac T. et al. A randomised phase IIIB trial of chemotherapy, bevacizumab and panitumumab compared with chemotherapy and bevacizumab alone for metastatic colorectal cancer. J Clin Oncol 2009;27 (5):672–80.Hecht J. R., Mitchell E., Chidiac T. et al. A randomised phase IIIB trial of chemotherapy, bevacizumab and panitumumab compared with chemotherapy and bevacizumab alone for metastatic colorectal cancer. J Clin Oncol 2009;27 (5):672–80.